Executive Summary
Choosing the right cell and gene therapy CDMO extends far beyond cost and timelines. Sponsors must evaluate GMP manufacturing capability, quality systems, scalability, and long-term alignment. This white paper provides a structured framework for assessing CDMO partners across development, technology transfer, and commercial readiness. Download the guide to learn how to move beyond the RFP and select a partner equipped to support your program from early-stage development through commercialization.
Key Takeaways
– A practical framework for evaluating cell and gene therapy CDMOs
– How to assess GMP manufacturing and scalability
– Practical questions to guide CDMO selection decisions
– Strategic considerations beyond pricing and timelines
Download the full white paper to explore the complete evaluation framework and practical decision guide.
About This White Paper
Selecting your cell and gene therapy CDMO is one of the most consequential decisions in advanced therapy development. Traditional RFP comparisons often focus on price, scope, and timelines, but may overlook deeper operational capabilities that affect regulatory success and commercialization. Gaps in GMP manufacturing infrastructure, quality systems, or technology transfer execution can introduce significant program risk.
This white paper outlines a structured evaluation framework designed specifically for cell and gene therapy sponsors. It highlights how to assess integrated capabilities across cell therapy manufacturing, gene therapy CDMO services, and viral vector production. The guide also emphasizes the importance of scalable GMP systems, strong quality governance, and long-term capacity planning.
A CDMO partnership should enable growth, not create bottlenecks. By moving beyond transactional RFP comparisons and evaluating strategic alignment, sponsors can reduce risk, strengthen regulatory readiness, and build a foundation for sustainable commercialization.
Who Should Read This White Paper?
– Biotech and pharma leaders evaluating cell and gene therapy CDMOs
– CMC and technical operations teams preparing for clinical manufacturing
– Quality and regulatory professionals assessing GMP readiness
– Business development teams conducting CDMO due diligence
– Sponsors planning long-term commercial supply strategies
